Effects of recombinant human canstatin protein in the treatment of pancreatic cancer

摘要: AIM: To examine the effect of canstatin, a newly discovered endogenous inhibitor angiogenesis, in treatment pancreatic cancer vivo. METHODS: The canstatin cDNA fragment was synthesized and amplified from total RNA extracted human placenta tissues by RT-PCR. resulting product firstly cloned into pUCm-T vector, then plasmid pET-22b (+) transformed E. coli BL21. Isopropyl-1-thio-b-Dgalactopyran-oside (IPTG) used to induce expression protein affinity chromatography purify protein. determine activity purified recombinant (rhCanstatin), orthotopic xenograft models were established. Human cells (SW1990) injected pancreas BALB/c nude mice. Twenty-four mice with tumor randomly divided 3 groups 10 d after inoculation, treated PBS 0.3 mL, or 5 mg/kg, mg/kg per day for wk intraperitoneally. When experiment over, all tumors resected effects rhCanstatin on growth, microvessel density (MVD) analyzed. RESULTS: After IPTG induction, SDS-PAGE showed new monomeric 24 kDa band. This through refolded dialysis final concentration 60 mg/L. In models, volume PBS, 355.21 ± 39.54 mm3, 112.73 10.47 61.75 6.99 mm3 respectively. immunohistochemical examination that MVD significantly less than other group. CONCLUSION: These findings demonstrate effectively retards growth dose-dependent manner inhibiting angiogenesis may be promising therapeutic agent clinic.